INSM
$39.47
Insmed
$.29
.74%
INSM
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.62)
Revenue:  $50.70 Mil
Thursday
Jan 28
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when INSM reports earnings?
Beat
Meet
Miss

Where is INSM's stock price going from here?
Up
Flat
Down
Stock chart of INSM
Analysts
Summary of analysts' recommendations for INSM
Score
Grade
Pivots
Resistance
$41.71
$40.85
$40.02

$39.16

Support
$38.32
$37.46
$36.63
Tweet
Growth
Description
Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly